{"id":39751,"date":"2025-08-20T13:20:44","date_gmt":"2025-08-20T05:20:44","guid":{"rendered":"https:\/\/flcube.com\/?p=39751"},"modified":"2025-08-20T13:20:44","modified_gmt":"2025-08-20T05:20:44","slug":"innocare-pharmas-orelabrutinib-powers-74-3-revenue-surge-in-2025-h1","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39751","title":{"rendered":"InnoCare Pharma&#8217;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1"},"content":{"rendered":"\n<p>Beijing-based biotech InnoCare Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.<\/p>\n\n\n\n<p><strong>Revenue Breakdown<\/strong><br>Drug revenue alone experienced a robust 53.5% year-on-year growth, reaching RMB 640 million in H1 2025. This uptick is largely attributed to orelabrutinib&#8217;s performance following its inclusion in China&#8217;s National Reimbursement Drug List (NRDL), especially for its exclusive marginal zone lymphoma indication. The company&#8217;s commercialization team has also played a pivotal role in driving this growth.<\/p>\n\n\n\n<p><strong>Profitability and Efficiency<\/strong><br>InnoCare Pharma&#8217;s net loss for the first half of 2025 contracted by 86.7% year-on-year to RMB 36 million. This substantial reduction is a testament to the company&#8217;s increased operating revenue and enhanced cost efficiency initiatives.<\/p>\n\n\n\n<p><strong>R&amp;D and Innovation<\/strong><br>The company has ramped up its R&amp;D expenditure by 6.9% year-on-year to RMB 450 million in H1 2025. This investment is geared towards establishing a differentiated R&amp;D platform and propelling more Phase III clinical projects forward.<\/p>\n\n\n\n<p><strong>Global Strategic Moves<\/strong><br>InnoCare Pharma has further expanded its global footprint through strategic collaborations. In January 2025, the company entered into partnerships with Conon Biotherapeutics and Prolium Bioscience to license the development and commercialization of the CD20\u00d7CD3 bispecific antibody ICP-B02 (CM355) to Prolium, marking a significant step in its global product development and commercialization strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688428_20250820_EW40.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688428_20250820_EW40.\"><\/object><a id=\"wp-block-file--media-1bbe022d-2595-49a5-a388-d69eb4f7a84e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688428_20250820_EW40.pdf\">688428_20250820_EW40<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/688428_20250820_EW40.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-1bbe022d-2595-49a5-a388-d69eb4f7a84e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":39756,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,919,327,920],"class_list":["post-39751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma&#039;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39751\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma&#039;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1\" \/>\n<meta property=\"og:description\" content=\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39751\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T05:20:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma&#8217;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1\",\"datePublished\":\"2025-08-20T05:20:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751\"},\"wordCount\":258,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2008.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39751#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39751\",\"name\":\"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2008.webp\",\"datePublished\":\"2025-08-20T05:20:44+00:00\",\"description\":\"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39751\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2008.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2008.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39751#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma&#8217;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1 - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39751","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1","og_description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.","og_url":"https:\/\/flcube.com\/?p=39751","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-20T05:20:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39751#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39751"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma&#8217;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1","datePublished":"2025-08-20T05:20:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39751"},"wordCount":258,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39751#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","keywords":["Finanical Reports","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39751#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39751","url":"https:\/\/flcube.com\/?p=39751","name":"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39751#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39751#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","datePublished":"2025-08-20T05:20:44+00:00","description":"Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428)\u00a0has unveiled its 2025 interim results, showcasing a remarkable 74.3% year-on-year revenue jump to RMB 730 million for the first half of the year. This significant growth is predominantly fueled by the escalating sales volume of its cornerstone drug, orelabrutinib, and a licensing agreement upfront payment from Prolium.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39751#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39751"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39751#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","width":1080,"height":608,"caption":"InnoCare Pharma's Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39751#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma&#8217;s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2008.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39751"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39751\/revisions"}],"predecessor-version":[{"id":39757,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39751\/revisions\/39757"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39756"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}